We are focused on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours.
Macomics is an immuno-oncology company with world-leading expertise in macrophage biology
Our new website is coming soon
July 14th 2020 -Macomics, an immuno-oncology company, secures £3.2 million seed funding from Epidarex Capital & the Scottish Investment Bank
Macomics are a UK-based drug discovery company working on first-in-class therapeutics that enhance the immune system by inhibiting the activities of tumour-associated macrophages (TAMs).
We're achieving this by employing world-class science, and novel candidate screening and validation technologies developed by our founders. All supported by an experienced team of executives and scientists.